| Name | AMPK-IN-3 |
| Description | AMPK-IN-3 is a novel, selective and potent AMPK inhibitor with inhibitory effects on AMPK (α2), AMPK (α1) and KDR, with IC50 values of 60.7, 107 and 3820 nM, respectively.AMPK-IN-3 showed anticancer activity in K562 cells. |
| In vitro | At a concentration of 100 nM, AMPK-IN-3 exhibits inhibition values of 64%, 43%, 41%, and 29% for AMPK(α2), FLT1, JAK1 JH2-pseudokinase, and AMPK(α1), respectively[1].In K562 cells, AMPK-IN-3, when applied at concentrations of 0.195313, 0.78125, 3.125, 12.5, and 50 µM for 2 hours, reduces the level of p-ACC[1].
For a duration of 24, 48, and 72 hours, AMPK-IN-3, within the concentration range of 1-100 µM, demonstrates potent inhibition of cellular AMPK activity without affecting cell viability[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (110.73 mM), Sonication is recommended.
|
| Keywords | KDR | AMPK |
| Inhibitors Related | Sorafenib | glycine | Nintedanib esylate | Chromium(III) acetate | Methyl cinnamate | Ethyl cinnamate | Metformin hydrochloride | Chitosan oligosaccharide | Isovaleric acid | Lenvatinib | Danthron | Pazopanib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Pyroptosis Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | Metabolism Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
United States
